Search for stocks /

Vikram Thermo (India) Ltd Q3 FY26 – ₹34 Cr Sales, ₹11 Cr PAT, 44% OPM… But Why Is ROE Only 6.5%?


1. At a Glance – The Pharma “Polymer King”… or Just a Fancy Coating Company?

Let me paint you a picture.

A company that makes pharma polymers — the invisible ingredient inside your tablet that decides whether your medicine works slowly, fast, or like a Bollywood climax… suddenly.

Margins? A juicy 39–45% OPM.
Debt? Practically zero.
Cash flows? Decent.
Promoter holding? A tight Gujarati family control at 66%.

Sounds like a hidden multibagger, right?

Now hold your chai.

Despite all this, the company’s ROE is just 6.53%.
Profit growth over 5 years? A sleepy 1.24%.
Recent sales growth? Negative (-1.7%).

And oh, they just did a demerger in 2024 — which is either:

  • A genius restructuring move
  • Or a classic “let’s rearrange the furniture and hope investors don’t notice”

So here’s the mystery:

How does a company with 40% margins, zero debt, and strong niche products… still manage mediocre returns?

Is this:

  • A hidden gem waiting to rerate?
  • Or a well-packaged “meh” business?

Let’s investigate like a proper Indian detective with a calculator.


2. Introduction – Pharma Ka Fevicol

Vikram Thermo (India) Ltd is not your typical pharma company.

They don’t make drugs.

They make the thing that makes drugs work properly.

Think of them as:

  • The Fevicol of pharma
  • The “background dancer” of tablets
  • The guy who ensures your medicine doesn’t dissolve at the wrong time

And in pharma, timing is everything:

  • Too early → no effect
  • Too late → no effect
  • Perfect timing → FDA smiles

That’s where pharma polymers come in.

Now the interesting part:
This isn’t a commodity chemical business. It’s application-driven chemistry — where formulation expertise matters.

So in theory:

  • High entry barriers
  • Sticky customers
  • Strong margins

But in reality?

Growth looks like it’s stuck in traffic near Andheri signal.

So the big question is:

Is this a niche moat… or just a niche excuse for slow growth?


3. Business Model – WTF Do They Even Do?

Let’s simplify this like explaining to your cousin who just opened a Demat account.

Core Business Buckets:

1. Pharma Polymers

These are used in:

  • Controlled drug release
  • Taste masking
  • Coating tablets

Basically:
They decide whether your Crocin melts in 10 minutes or 10 hours.


2. Cosmetic Polymers

Used in:

  • Creams
  • Gels
  • Personal care

Translation:
They help your fairness cream feel premium even if it’s not.


3. Ion Exchange Polymers

Used for:

  • Taste masking
  • Oral formulations

Because apparently, pharma companies also care about not making medicine taste like poison.


Brands:

  • Drug Coat
  • DRCoat
  • AquaPol
  • Apion

Sounds fancy, but all revolve around formulation chemistry.


Capacity:

  • Total ~10,000 TPA across 2 plants

Revenue Mix:

  • 99% from finished goods

Good sign: Not a trading business.


My Take:

This is a B2B niche chemical + pharma hybrid.

But here’s the catch:

If your customers don’t grow… you don’t grow.

So tell me:

Would you rather own:

  • A niche supplier with high margins
  • Or a mass player with high growth?

4. Financials Overview – Numbers Don’t Lie (But They Do Confuse)

Quarterly Comparison (₹ Crores)

MetricDec 2025Dec

Eduinvesting Team

Leave a Reply

Don't Miss

error: Content is protected !!